Pain Clinical Trial
Official title:
A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) Prolonged Release (PR*) in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain. *Prolonged Release and is the Recommended Nomenclature for Use in the European Union (EU). ER Means Extended Release and is the Recommended Nomenclature for Use in the United States of America (USA). "PR" is Synonymous With "ER" and is Interchangeable.
The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
Normally chronic tumor related pain is controlled when subjects receive repeated doses of
opioid analgesics. However, opioid therapy is commonly associated with side effects such as
nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression.
Tapentadol, a newly synthesized drug with an Prolonged Release (ER) formulation, also acts as
a centrally acting pain reliever but has a dual mode of action.
The aim of this trial is to investigate the effectiveness (level of pain control) and safety
(side effects) of Tapentadol Prolonged Release (ER) compared to a tablet with no active
ingredient drug (placebo) and a corresponding dose of Morphine (an opioid commonly used to
treat tumor related pain). This trial is a randomized, double-blind (neither investigator nor
patient will know which treatment was received), active- and placebo-controlled,
parallel-group, randomized-withdrawal, multicenter trial. To maintain the blind all subjects
were re-randomized at the start of the maintenance period. To maintain the blind all
tapentadol subjects were re-randomized at the start of the maintenance period. Subjects that
received morphine in the titration period continued in the maintenance period on morphine.
The trial includes a 2 week titration phase starting with either 45 mg Morphine Sulfate
Controlled Release (CR) twice daily or 100 mg tapentadol ER taken twice daily (bid). Based on
effectiveness and side effects participants can up-titrate in steps of 50 mg Tapentadol ER or
15 mg Morphine Sulfate CR to a maximal dose of 250 mg Tapentadol ER bid or 90 mg Morphine
Sulfate CR twice daily respectively. If subjects meet the stabilization criteria at the end
of the titration phase they will be re-randomized to either placebo or active treatment and
will continue 4 weeks at the last dose level in the maintenance phase.
Assessments of pain relief, defined as a responder include the pain intensity numeric rating
scale (NRS). The Patient Global Impression of Change scale (PGIC) will also be used as a
secondary efficacy endpoint. Safety evaluations include monitoring of adverse events,
physical examinations, and clinical laboratory tests. Venous blood samples will be collected
for the determination of serum concentrations of tapentadol.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
| Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
| Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
| Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
| Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
| Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
| Recruiting |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
| Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
| Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
| Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
| Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
| Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
| Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
| Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
| Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
| Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
| Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
| Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
| Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|